Activating mutations of STAT5B and STAT3 in lymphomas derived from γδ-T or NK cells

Can Küçük, Bei Jiang, Xiaozhou Hu, Wenyan Zhang, John K.C. Chan, Wenming Xiao, Nathan Lack, Can Alkan, John C. Williams, Kendra N. Avery, Painar Kavak, Anna Scuto, Emel Sen, Philippe Gaulard, Lou Staudt, Javeed Iqbal, Weiwei Zhang, Adam Cornish, Qiang Gong, Qunpei YangHong Sun, Francesco D'Amore, Sirpa Leppä, Weiping Liu, Kai Fu, Laurence De Leval, Timothy McKeithan, Wing C. Chan

Research output: Contribution to journalArticlepeer-review

323 Scopus citations


Lymphomas arising from NK or γδ-T cells are very aggressive diseases and little is known regarding their pathogenesis. Here we report frequent activating mutations of STAT3 and STAT5B in NK/T-cell lymphomas (n=51), γδ-T-cell lymphomas (n=43) and their cell lines (n=9) through next generation and/or Sanger sequencing. STAT5B N642H is particularly frequent in all forms of γδ-T-cell lymphomas. STAT3 and STAT5B mutations are associated with increased phosphorylated protein and a growth advantage to transduced cell lines or normal NK cells. Growth-promoting activity of the mutants can be partially inhibited by a JAK1/2 inhibitor. Molecular modelling and surface plasmon resonance measurements of the N642H mutant indicate a marked increase in binding affinity of the phosphotyrosine-Y699 with the mutant histidine. This is associated with the prolonged persistence of the mutant phosphoSTAT5B and marked increase of binding to target sites. Our findings suggest that JAK-STAT pathway inhibition may represent a therapeutic strategy.

Original languageEnglish (US)
Article number6025
JournalNature communications
StatePublished - Jan 2015

ASJC Scopus subject areas

  • General Physics and Astronomy
  • General Chemistry
  • General Biochemistry, Genetics and Molecular Biology


Dive into the research topics of 'Activating mutations of STAT5B and STAT3 in lymphomas derived from γδ-T or NK cells'. Together they form a unique fingerprint.

Cite this